midazolam hydrochloride / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

24 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
midazolam hydrochloride / Generic mfg.
ACTRN12614000982617: The effect of dexamethasone on single-shot adductor canal blockade in total knee arthroplasty: a pilot study

Not yet recruiting
2
30
 
Fremantle Hospital and Health Services, Fremantle and Kaleeya Hospitals Fremantle Hospital Medical Research Foundation
Post operative pain management , Total knee arthroplaty
 
 
ACTRN12606000148572: Epidural Versus Intrathecal Analgesia in Abdominal Surgery - the EVITA study

Not yet recruiting
2
100
 
Dr Michael Duncan
Pain relief and recovery after surgical resection of the stomach, small bowel or colon.
 
 
ACTRN12621000052831: DREAMS: Comparing dexmedetomidine versus midazolam at the end of life for sedative and anti-agitation effects

Recruiting
2
52
 
Dr Benjamin Thomas, Illawarra Shoalhaven Local Health District
Distress at the end of life, Sedation at the end of life
 
 
ChiCTR-OCS-13004773: Phase IIa Trial of Isoflurane injection

Completed
2
180
 
isoflurane injection
West China Hospital, Sichuan University; Level of the institution:, Yichang HumanWell Pharmaceutical Co.,Ltd
Induction of anesthesia
 
 
2007-006087-30: Prospektive randomisierte klinische Studie zur Beurteilung der Effizienz und Sicherheit einer inhalativen Sedierung mit Sevofluran im Vergleich zu einem intravenösen Sedierungskonzept mit Propofol bei langzeitsedierten Intensivpatienten

Ongoing
2
100
Europe
Sevofluran, Propofol, Midazolam, Sevorane, Disoprivan 2 %, Dormicum Injektionslösung, Sevorane, Disoprivan 2 %, Dormicum Injektionslösung
Martin-Luther-Universität Halle-Wittenberg, vertreten durch den Kanzler
Intensivmedizinische Patienten mit erforderlicher Langzeitsedierung.
 
 
2010-018992-16: Evaluation pharmacocinétique de MDZ028 après administration unique d\'une forme orale nouvelle, lors de la prémédication anesthésique chez l\'enfant.

Ongoing
2
36
Europe
midazolam, MDZ028,
Centre hospitalier universitaire d\'Amiens
prémédication anesthésique
 
 
2019-001139-30: A study to investigate whether RO707049389 is safe and how it is processed by the body, and its antiviral effect at different dose levels and in different population (healthy people, patients infected with hepatitis B virus and patients had chronic active hepatitis B)

Not yet recruiting
2
55
Europe
RO7049389, Ro 7049389/F09, Film-coated tablet
F. Hoffman-La Roche Ltd., F. Hoffmann-La Roche Ltd.
Chronic Hepatitis B, chronic liver disease caused by chronic hepatitis B virus infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT05186454: Postoperative Pain Control by Use of Many Drugs in Small Doses Intrathecally

Recruiting
2
60
RoW
Morphine Sulfate, bupivacaine, Bupivacaine, dexamethasone, morphine, midazolam
Sohag University
Post Operative Pain
02/22
02/22
BLC2001, NCT02365597 / 2014-002408-26: An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Checkmark Long term data from BLC2001 study for locally advanced/metastatic urothelial carcinoma
May 2020 - May 2020: Long term data from BLC2001 study for locally advanced/metastatic urothelial carcinoma
Checkmark Submitted for the treatment of locally advanced or metastatic urothelial cancer (2L)
Sep 2018 - Sep 2018: Submitted for the treatment of locally advanced or metastatic urothelial cancer (2L)
Checkmark In the treatment of metastatic urothelial cancer
More
Active, not recruiting
2
239
Europe, US, RoW
Erdafitinib, JNJ-42756493, Midazolam, Metformin
Janssen Research & Development, LLC
Urothelial Cancer
09/22
12/24
2020-000229-24: An Open-label Drug-Drug Interaction Study to Assess the Effects ofNemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Serve Atopic Dermatitis

Not yet recruiting
2
25
Europe
Nemolizumab, CD14152, Powder and solution for solution for injection, Solution for injection, Tablet, Midazolam Injection, USP, MsKesson Omeprazole Delayed Release Tablets 20 mg, WARFARIN SODIUM – warfarin sodium tablet, JET-ALERT Regular Strength, Metoprolol Tartrate Tablets, USP
Galderma S.A., Galderma S.A.
Moderate-to-severe atopic dermatitis, Atopic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT04562116: A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

Completed
2
16
Europe, US
Nemolizumab, CD14152, CYP 450 Substrates
Galderma R&D
Atopic Dermatitis
06/23
06/23
2022-003381-21: Regression of atherosclerosis induced by life changing experience with psilocybin Regrese aterosklerózy navozená život měnící zkušeností s psilocybinem

Not yet recruiting
2
60
RoW
PSILOCYBIN, MIDAZOLAM, D0000407, Capsule
Psyon, s.r.o., Psyon, s.r.o., Nadační fond pro výzkum psychedelik
Ischemic Heart Disease Ischemická choroba srdeční, Ischemic Heart Disease Ischemická choroba srdeční, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04873596: Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia

Recruiting
2
94
RoW
Nebulized dexmedetomidine, precedex, Nebulized midazolam, Dormicum
Zagazig University
Procedural Sedation
06/24
08/24
REST, NCT06275594: Trial Evaluating the Efficacy of Remimazolam in Endobronchial Ultrasound Guided Transbronchial Needle Aspiration

Not yet recruiting
2
330
RoW
Byfavo, Remimazolam, Midazolam
Yeungnam University Hospital
Midazolam, Remimazolam
02/25
02/25
MIRAGE, NCT06638710: Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient with Neurocognitive Disorders and Refusing Care.

Not yet recruiting
2
30
Europe
oral administration of midazolam or placebo
University Hospital, Grenoble
Neurocognitive Disorders
06/26
11/26
NCT04033471: Combined Epidural Morphine and Midazolam on Postoperative Pain

Recruiting
1/2
20
RoW
midazolam, morphine, bupivacaine
Assiut University
Acute Postoperative Pain
03/21
04/21
NCT06072248: Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation

Completed
1/2
200
RoW
Meropenem, bronchoscopy, ventilator
King Abdul Aziz Specialist Hospital
ARDS, Septic Shock
12/21
12/21
NCT06072222: Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation

Completed
1/2
200
RoW
Meropenem, bronchoscopy, ventilator
King Abdul Aziz Specialist Hospital
ARDS, Septic Shock
12/21
12/21
NCT05610969: Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks

Recruiting
1/2
160
US
Music, Midazolam, Hypnovel, Versed
University of Pennsylvania
Peripheral Nerve Block, Anxiety, Preoperative Anxiety
09/24
09/24
NCT06126991: Organ Protective Effect of Cetirizine In Patients With Severe Burns

Recruiting
1/2
32
RoW
Cetirizine, Midazolam and Fentanyl
Ruijin Hospital
Burns
12/24
12/25
CYPIDES, NCT03436485 / 2017-002534-23: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
1/2
204
Europe, US
ODM-208, Midazolam
Orion Corporation, Orion Pharma
Prostate Cancer Metastatic
12/24
12/24
C4391001, NCT04557449: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Recruiting
1/2
337
Europe, Japan, US, RoW
PF-07220060, Letrozole, Femara, Fulvestrant, Faslodex, Midazolam, Enzalutamide, Xtandi
Pfizer
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
09/26
11/27
CodeBreak 100, NCT03600883 / 2018-001400-11: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
Active, not recruiting
1/2
713
Europe, Canada, Japan, US, RoW
sotorasib, Anti PD-1/L1, Midazolam
Amgen
KRAS p.G12C Mutant Advanced Solid Tumors
05/28
05/28
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28

Download Options